Adverse Cardiovascular Events in Cancer Trials: Missing in Action?

J Am Coll Cardiol. 2020 Feb 18;75(6):629-631. doi: 10.1016/j.jacc.2019.12.019.

Authors

Nanette H Bishopric¹, Marc E Lippman²

Affiliations

¹ MedStar Heart and Vascular Institute, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC. Electronic address: nhb20@georgetown.edu.
² Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC.

PMID: 32057378
DOI: 10.1016/j.jacc.2019.12.019

No abstract available

Keywords: U.S. Food and Drug Administration; cancer clinical trials; cardio-oncology; cardiovascular disease; reporting of adverse events.

Publication types

Editorial
Comment

MeSH terms

Adverse Drug Reaction Reporting Systems
Cardiovascular Diseases*
Humans
Neoplasms*